Logo image of SLRN

ACELYRIN INC (SLRN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLRN - US00445A1007 - Common Stock

2.27 USD
+0.04 (+1.79%)
Last: 5/20/2025, 8:00:02 PM
2.25 USD
-0.02 (-0.88%)
After Hours: 5/20/2025, 8:00:02 PM
Fundamental Rating

3

Overall SLRN gets a fundamental rating of 3 out of 10. We evaluated SLRN against 529 industry peers in the Biotechnology industry. While SLRN has a great health rating, there are worries on its profitability. SLRN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLRN had negative earnings in the past year.
In the past year SLRN has reported a negative cash flow from operations.
SLRN Yearly Net Income VS EBIT VS OCF VS FCFSLRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

SLRN has a Return On Assets of -61.52%. This is comparable to the rest of the industry: SLRN outperforms 40.71% of its industry peers.
SLRN has a Return On Equity of -65.94%. This is comparable to the rest of the industry: SLRN outperforms 57.68% of its industry peers.
Industry RankSector Rank
ROA -61.52%
ROE -65.94%
ROIC N/A
ROA(3y)-40.72%
ROA(5y)N/A
ROE(3y)-44.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLRN Yearly ROA, ROE, ROICSLRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLRN Yearly Profit, Operating, Gross MarginsSLRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

SLRN has more shares outstanding than it did 1 year ago.
SLRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SLRN Yearly Shares OutstandingSLRN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
SLRN Yearly Total Debt VS Total AssetsSLRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

SLRN has an Altman-Z score of 1.25. This is a bad value and indicates that SLRN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SLRN (1.25) is better than 68.93% of its industry peers.
SLRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.25
ROIC/WACCN/A
WACCN/A
SLRN Yearly LT Debt VS Equity VS FCFSLRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

SLRN has a Current Ratio of 18.43. This indicates that SLRN is financially healthy and has no problem in meeting its short term obligations.
SLRN has a better Current ratio (18.43) than 91.79% of its industry peers.
SLRN has a Quick Ratio of 18.43. This indicates that SLRN is financially healthy and has no problem in meeting its short term obligations.
SLRN has a better Quick ratio (18.43) than 91.96% of its industry peers.
Industry RankSector Rank
Current Ratio 18.43
Quick Ratio 18.43
SLRN Yearly Current Assets VS Current LiabilitesSLRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

SLRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.00%.
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.97% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.89%
EPS Next 2Y15.37%
EPS Next 3Y8.54%
EPS Next 5Y12.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLRN Yearly Revenue VS EstimatesSLRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SLRN Yearly EPS VS EstimatesSLRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLRN. In the last year negative earnings were reported.
Also next year SLRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLRN Price Earnings VS Forward Price EarningsSLRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLRN Per share dataSLRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.37%
EPS Next 3Y8.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACELYRIN INC

NASDAQ:SLRN (5/20/2025, 8:00:02 PM)

After market: 2.25 -0.02 (-0.88%)

2.27

+0.04 (+1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners89.36%
Inst Owner Change-13.72%
Ins Owners1.13%
Ins Owner Change0%
Market Cap229.16M
Revenue(TTM)N/A
Net Income(TTM)-268.52M
Analysts85
Price Target8.16 (259.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.26%
Min EPS beat(2)-7.84%
Max EPS beat(2)10.36%
EPS beat(4)2
Avg EPS beat(4)-1.58%
Min EPS beat(4)-11.91%
Max EPS beat(4)10.36%
EPS beat(8)5
Avg EPS beat(8)5.07%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.28%
EPS NY rev (1m)0%
EPS NY rev (3m)7.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-2.99
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS0
BVpS4.03
TBVpS4.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.52%
ROE -65.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.72%
ROA(5y)N/A
ROE(3y)-44.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 248.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.43
Quick Ratio 18.43
Altman-Z 1.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.78%
EPS Next Y26.89%
EPS Next 2Y15.37%
EPS Next 3Y8.54%
EPS Next 5Y12.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-77.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.09%
OCF growth 3YN/A
OCF growth 5YN/A

ACELYRIN INC / SLRN FAQ

What is the ChartMill fundamental rating of ACELYRIN INC (SLRN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLRN.


What is the valuation status of ACELYRIN INC (SLRN) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACELYRIN INC (SLRN). This can be considered as Overvalued.


What is the profitability of SLRN stock?

ACELYRIN INC (SLRN) has a profitability rating of 1 / 10.


How financially healthy is ACELYRIN INC?

The financial health rating of ACELYRIN INC (SLRN) is 7 / 10.